Navigation Links
Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference
Date:12/6/2011

SAN DIEGO, December 6, 2011 /PRNewswire/ --

Speaking today at the plenary session of the IBC's International Antibody Conference in San Diego, Dr. Klaus Schwamborn, CDO of Pepscan Therapeutics, presented Pepscan's protein mimicry platform for the discovery of therapeutic antibodies.

In his presentation 'CLIPS meets GPCRs' Dr. Schwamborn introduced the CLIPS technology and the most recent developments of immunogen design. He showed data demonstrating that Pepscan's synthetic immunogens induce potent antibodies against GPCRs and therefore are able to mimic the native receptor. Resulting antibodies do not only bind strongly to the native receptor, but also show functionality with neutralizing activity in different cell based assays. Pepscan's approach was applied to different targets, supporting the concept of a generic platform for antibody generation for any given GPCR.

Monoclonal antibody therapy is very successful and has major advantages compared to small molecule therapy. However, it is very difficult to generate monoclonal antibodies for certain important drug targets, due to technical constraints, and so far no generic approach has been documented. This is in particular valid for G-protein coupled receptors (GPCR's), for which no FDA approved antibody exists. Over the last years, Pepscan Therapeutics has validated and optimized its CLIPS technology which enables the design and synthesis of conformationally stabilized peptides with a well-defined 3D-structure, resembling the native functional protein surface. New immunogen design strategies were established which allow grafting extracellular domains of any given GPCR onto a synthetic template, mimicking the native receptor structure in an optimal way.

The platform provides a systematic and efficient way of making synthetic immunogens which induce antibodies against the native target. With these immunogens, monoclonal antibodies can be generated by using common antibody technologies
'/>"/>

SOURCE Pepscan Therapeutics BV
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pepscan Therapeutics Strengthens Management Team
2. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
3. Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing
4. FDA Sets April 24, 2012 as PDUFA Goal Date for Cell Therapeutics Resubmitted Pixantrone New Drug Application
5. GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018
6. Novelos Therapeutics Prices $5.9 Million Public Offering
7. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
8. Antiviral Therapeutics - Technologies, Markets and Companies
9. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
10. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
11. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013  The need to add ... continuum was highlighted prominently at the 108 th ... (AUA), in San Diego.  According to SonaCare Medical, ... ultrasound (HIFU) technology, the need for image-guided technologies ... urologists to consider minimally invasive ablative treatments, was ...
(Date:5/23/2013)...  Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good chance ... Gionfriddo , about her now 20-month-old son, Kaiba. "At ... would take it and run with it." They ...
(Date:5/23/2013)... 2013  Hologic, Inc. (Hologic or the Company) ... manufacturer and supplier of premium diagnostics, medical imaging ... serving the healthcare needs of women, today announced ... U.S. clinical practice comparing breast cancer screening with ... 2D mammography alone showed a significant reduction in ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4
(Date:5/23/2013)... Internationally recognized as one of the top developmental ... years, Coach Nick Saviano’s proven methodology has ... Slam winners, World #1’s; Junior Wimbledon, US Open, French ... Champions, 8 Foreign National Junior Champions and more than ... and Eddie Herr winners - and boasts a 100% ...
(Date:5/23/2013)... 2013 Orange County film studio and visual ... light leaks for Apple's Final Cut Pro X ... you no longer have to worry about matching up the ... shot," Said Christina Austin, CEO of Pixel Film Studios, "You ... natural look." , ProLeak from Pixel Film Studios allows users ...
(Date:5/23/2013)... 2013 Today, Zane Benefits, Inc. published ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution plans and health reimbursement ... question from employees is “does my employer have to ... necessarily. The health care reform law, called the Affordable ...
(Date:5/23/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Glucosamine ... hip and knee osteoarthritis may have an unexpected side ... small new study of older adults suggests. ... pressure (IOP) or pressure inside the eye. Left untreated, ... In the new study of 17 ...
(Date:5/23/2013)... Science published an article about bexarotene as ... important starting point for further Alzheimer,s research. The research ... VIB and KU Leuven in collaboration with the ... scientists at Janssen Pharmaceutica, Beerse, also tested this candidate ... were different, as were those of two American study ...
Breaking Medicine News(10 mins):Health News:Internationally Respected Tennis Coach, Nick Saviano Opens Summer Training Registration 2Health News:Pixel Film Studios Releases ProLeak Light Leaks for Final Cut Pro X Today 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:New insights contradict promising Alzheimer's research 2
... more difficult to recognize and treat epilepsy in old ... Deutsches rzteblatt International ( Dtsch Arztebl Int ... Epilepsy Center of Johannes Gutenberg University in Mainz, Germany, ... therapeutic options. , It is often not possible ...
... Pharmaceuticals, Inc. (Nasdaq: TSPT ), a specialty ... proprietary products that address important therapeutic needs in the ... for its fourth quarter 2008 on Monday, March 23, ... the results will begin at 5:00 p.m. ET (2:00 ...
... benefit from tonal training , , FRIDAY, March 13 (HealthDay ... emotion in speech and other sounds, a finding that ... problems and impaired emotional perception. , "Quickly and ... translates across all arenas, whether in the predator-infested jungle ...
... CONSHOHOCKEN, Pa., March 13 Apollo Health Street has ... Payer segment in the prestigious Black Book of Outsourcing ... Apollo Health Street, states, "We appreciate the recognition from ... is an independent validation of our commitment to excellence.""The ...
... in the Schering-Plough Corporation Securities Litigation class action suit ... COURT, DISTRICT OF NEW JERSEY, ... MASTER FILE NO. 01-CV-0829 (KSH/MF), , ... SECURITIES DURING THE PERIOD FROM MAY 9, 2000 THROUGH ...
... Study shows giving up your keys has its down sideSAN ... The Journals of Gerontology (Medical Sciences) indicate that convincing older ... such a good idea.The study of 660 adults aged 63 ... to six times more likely to die over a three-year ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 2Health News:Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results 3Health News:Musicians' Brains Tuned to Emotions in Sound 2Health News:Apollo Health Street Has Earned the Number One Spot in the Healthcare Payer Segment for BPO Services 2Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 2Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 3Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 4Health News:Drive or Die 2Health News:Drive or Die 3
... rate: 80 cc/minute. Pore ... filtering fluids at flow ... bi-directional membrane support rated ... psi) via prefilled syringe ...
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
Backward cutting, 3 mm x 7 mm bite, length of shaft 100 mm, overall length 7 inches....
Medicine Products: